Seattle Genetics has signed a collaboration and licence agreement with biotechnology firm Pieris Pharmaceuticals for the development of a variety of targeted bispecific immuno-oncology therapies to treat solid tumours and blood cancers.
Under the alliance, the firms aim to combine their respective expertise and technologies to create new Antibody-Anticalin fusion proteins.
The range of agonistic costimulatory Anticalin proteins by Pieris are designed to stimulate the immune system when attached to a tumour-targeting antibody, while programmes from Seattle Genetics鈥� cancer targets and tumour-specific monoclonal antibodies will be selected for this research.
Seattle Genetics Research senior vice-president Dennis Benjamin said: 鈥淧ieris鈥� Anticalin technology and Antibody-Anticalin bispecific approach are intended to overcome the limitations of currently available immuno-oncology products.
鈥淭his partnership leverages our cancer targets and tumour-specific antibodies to explore multiple novel bispecific combinations, with the goal of developing targeted therapies that improve outcomes for people with cancer.鈥�
Seattle Genetics and Pieris intend to design the new bispecific drug candidates in a way to activate the immune cells for specifically targeting tumours.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe agreement will see an upfront payment of $30m from Seattle Genetics to Pieris, which is also eligible for tiered royalties on net sales and around $1.2bn success-based payments covering three product candidates.
Of the various fusion proteins during the research phase, Seattle Genetics holds an option to select about three therapeutic programmes for further development.
While Pieris has an option to participate in global co-development and US commercialisation of one programme with a 50% share in global costs and profits, Seattle Genetics will be exclusively responsible for the development, funding and commercialisation of the remaining two programmes.
